| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 经修饰的ACE2多肽 | CN201480012988.1 | 2014-01-13 | CN105263512A | 2016-01-20 | H.洛伊布纳; B.佩巴尔; M.舒斯特; S.施特兰纳 |
| 本发明涉及经修饰的血管紧张素转换酶2（ACE2）多肽及其药物和分析用途。特别地，本发明涉及Zn2+耗尽、不含Zn2+、混合金属和金属离子取代的ACE2，以及用于制造这些变体的方法及其用途，例如这些ACE2变体的治疗和分析用途。 | ||||||
| 2 | Modified ACE2 polypeptides | US14760529 | 2014-01-13 | US20150353910A1 | 2015-12-10 | Hans LOIBNER; Bernhard PEBALL; Manfred SHUSTER; Stefan STRANNER |
| The present invention relates to modified angiotensin converting enzyme 2 (ACE2) polypeptides and pharmaceutical and analytical uses thereof. In particular, the present invention relates to Zn2+ depleted-, Zn2+ free-, mixed metal- and metal ion substituted-ACE2 as well as methods for the manufacture of these variants and uses thereof, such as therapeutic and analytic uses of these ACE2 variants. | ||||||
| 3 | Treatment of tumors | US12937029 | 2009-04-07 | US08946162B2 | 2015-02-03 | Evelyne Janzek-Hawlat; Hans Loibner; Manfred Schuster; Bernhard Peball |
| The invention provides for innovative improvements in tumor therapy, particularly therapies which are conducted using endogenous substances and which have no or only mild side-effects. Accordingly the present invention relates to methods of treating or preventing tumor diseases other than lung cancer comprising administering a polypeptide with an angiotensin-converting-enzyme-2 (ACE2) activity. | ||||||
| 4 | 腫瘍疾患の治療 | JP2011503304 | 2009-04-07 | JP5650639B2 | 2015-01-07 | ハンザック−ホウラット，エブリン; ロイブナー，ハンス; シャスター，マンフレッド; ピボール，ベルンハード |
| 5 | Behandlung von Tumorerkrankungen | EP13162709.3 | 2009-04-07 | EP2644203A1 | 2013-10-02 | Janzek-Hawlat, Evelyne; Loibner, Hans; Schuster, Manfred; Peball, Bernhard |
Beschrieben wird die Verwendung eines Polypeptids mit einer Angiotensin konvertierenden Enzym 2 (angiotensin converting enzyme 2; ACE2)-Aktivität zur Herstellung eines Medikaments zur Behandlung von Tumorerkrankungen. |
||||||
| 6 | 改変ＡＣＥ２ポリペプチド | JP2015552067 | 2014-01-13 | JP2016504042A | 2016-02-12 | ロイブナー，ハンス; ペバル，ベルンハルト; シュースター，マンフレート; シュトランナー，シュテファン |
| 本発明は改変アンジオテンシン変換酵素2(ACE2)ポリペプチドならびにその医薬および分析用途に関する。特に、本発明はZn2+枯渇、Zn2+非含有、混合金属および金属イオン置換ACE2、ならびにこれらの変異体の製造方法およびその用途、例えば、これらのACE2変異体の治療および分析用途に関する。【選択図】なし | ||||||
| 7 | The treatment of tumor diseases | JP2011503304 | 2009-04-07 | JP2011516501A | 2011-05-26 | シャスター，マンフレッド; ハンザック−ホウラット，エブリン; ピボール，ベルンハード; ロイブナー，ハンス |
| 本発明は、腫瘍疾患の治療薬の製造のためのアンギオテンシン変換酵素２（angiotensin converting enzyme 2；ACE2）活性を有するポリペプチドの使用に関する。 | ||||||
| 8 | ACTIVE LOW MOLECULAR WEIGHT VARIANTS OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) | US15878823 | 2018-01-24 | US20180230447A1 | 2018-08-16 | Daniel Batlle; Jan Wysocki |
| Disclosed are variants of ACE2, pharmaceutical compositions comprising the variants of ACE2, and treatment methods for reducing Angiotensin II (1-8) plasma levels and/or increasing Angiotensin (1-7) plasma levels in a subject in need thereof. The disclosed variants of ACE2 may include polypeptide fragments of ACE2 having ACE2 activity for converting AngII(1-8) to Ang(1-7). Suitable subjects suitable for the disclosed methods of treatment may include subjects having or at risk for developing diabetic and non-diabetic chronic kidney disease, acute renal failure and its prevention, chronic kidney disease, severe hypertension, scleroderma and its skin, pulmonary, kidney and hypertensive complications, malignant hypertension, renovascular hypertension secondary to renal artery stenosis, idiopathic pulmonary fibrosis, liver fibrosis such as in liver cirrhosis patients, an aortic aneurysm, cardiac fibrosis and remodeling, left ventricular hypertrophy, and an acute stroke. | ||||||
| 9 | TREATMENT OF INFLAMMATORY ILLNESSES WITH ACE2 | US15724719 | 2017-10-04 | US20180117126A1 | 2018-05-03 | Hans LOIBNER; Manfred Schuster |
| The present invention relates to ACE2 for the therapeutic treatment or prevention of inflammation. | ||||||
| 10 | Modified ACE2 polypeptides | US14760529 | 2014-01-13 | US09757433B2 | 2017-09-12 | Hans Loibner; Bernhard Peball; Manfred Schuster; Stefan Stranner |
| The present invention relates to modified angiotensin converting enzyme 2 (ACE2) polypeptides and pharmaceutical and analytical uses thereof. In particular, the present invention relates to Zn2+ depleted-, Zn2+ free-, mixed metal- and metal ion substituted-ACE2 as well as methods for the manufacture of these variants and uses thereof, such as therapeutic and analytic uses of these ACE2 variants. | ||||||
| 11 | ORAL DELIVERY OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) OR ANGIOTENSIN-(1-7) BIOENCAPSULATED IN PLANT CELLS ATTENUATES PULMONARY HYPERTENSION, CARDIAC DYSFUNCTION AND DEVELOPMENT OF AUTOIMMUNE AND EXPERIMENTALLY INDUCED OCULAR DISORDERS | US15030377 | 2016-04-18 | US20160331816A1 | 2016-11-17 | Henry DANIELL; Qiuhong LI; Mohan K. RAIZADA |
| Emerging evidence indicates that diminished activity of the vasoprotective axis of the renin-angiotensin system, constituting angiotensin converting enzyme2 (ACE2) and its enzymatic product, angiotensin-(1-7) [Ang-(1-7)] contribute to pulmonary hypertension (PH). However, clinical success for long-term delivery of ACE2 or Ang-(1-7) would require stability and ease of administration to increase patient compliance. Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect from acids and gastric enzymes; fusion to a transmucosal carrier facilitates effective systemic absorption. Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) attenuated monocrotaline (MCT)-induced increase in right ventricular systolic pressure, decreased pulmonary vessel wall thickness and improved right heart function in both prevention and reversal protocols. Furthermore, combination of ACE2 and Ang-(1-7) augmented the beneficial effects against cardio-pulmonary pathophysiology induced by MCT administration.Experiments have also been performed which indicate that this approach is also suitable for the treatment or inhibition of experimental uveitis and autoimmune uveoretinitis These studies provide proof-of-concept for a novel low-cost oral ACE2 or Ang-(1-7) delivery system using transplastomic technology for pulmonary and ocular disease therapeutics. | ||||||
| 12 | TREATMENT OF TUMORS | US12937029 | 2009-04-07 | US20110033524A1 | 2011-02-10 | Evelyne Janzek-hawlat; Hans Loibner; Manfred Schuster; Bernhard Peball |
| The invention provides for innovative improvements in tumour therapy, particularly therapies which are conducted using endogenous substances and which have no or only mild side-effects. Accordingly the present invention relates to methods of treating or preventing tumor diseases other than lung cancer comprising administering a polypeptide with an angiotensin-converting-enzyme-2 (ACE2) activity. | ||||||
| 13 | APHERESIS, ADMINISTRATION OF AGENT, OR COMBINATION THEREOF | US12852170 | 2010-08-06 | US20110033463A1 | 2011-02-10 | Deepak R. Thakker; Lisa L. Shafer |
| A device is configured to remove a target molecule from a bodily fluid of a subject and to deliver a therapeutic agent to the subject. Such a device may be used for treatment of a disease associated with amyloid beta accumulation in the subject. Agents selected from the group consisting of an ApoE-modulating agent; a RAGE inhibitor; a β-secretase 1 (BACE1) inhibitor; a γ-secretase inhibitor; a muscarinic receptor subtype 1 (M1) agonists; a growth factor; an enzyme capable of degrading amyloid beta; a mitochondrial antioxidant; insulin; and an inhibitor of tumor necrosis factor (TNF) may be administered directly to the central nervous system of a subject for treatment of a disease associated with amyloid beta accumulation. | ||||||
| 14 | ORAL DELIVERY OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) OR ANGIOTENSIN-(1-7) BIOENCAPSULATED IN PLANT CELLS | EP14854090.9 | 2014-10-20 | EP3058074A1 | 2016-08-24 | DANIELL, Henry; LI, Qiuhong; RAIZADA, Mohan, K. |
| Experiments have also been performed which indicate that this approach is also suitable for the treatment or inhibition of experimental uveitis and autoimmune uveoretinitis These studies provide proof-of-concept for a novel low-cost oral ACE2 or Ang-(1-7) delivery system using transplastomic technology for pulmonary and ocular disease therapeutics. | ||||||
| 15 | BEHANDLUNG VON TUMORERKRANKUNGEN DURCH ANGIOTENSIN KONVERTIERENDES ENZYM 2 (ACE2) | EP09730771.4 | 2009-04-07 | EP2274005B1 | 2013-05-29 | JANZEK-HAWLAT, Evelyne; LOIBNER, Hans; SCHUSTER, Manfred; PEBALL, Bernhard |
| 16 | BEHANDLUNG VON TUMORERKRANKUNGEN | EP09730771.4 | 2009-04-07 | EP2274005A2 | 2011-01-19 | JANZEK-HAWLAT, Evelyne; LOIBNER, Hans; SCHUSTER, Manfred; PEBALL, Bernhard |
| The invention relates to the use of a polypeptide having an angiotensin converting enzyme 2 (ACE2) activity for producing a drug for treating tumors. | ||||||
| 17 | ORAL DELIVERY OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) OR ANGIOTENSIN-(1-7) BIOENCAPSULATED IN PLANT CELLS | EP14854090 | 2014-10-20 | EP3058074A4 | 2017-05-24 | DANIELL HENRY; LI QIUHONG; RAIZADA MOHAN K |
| Experiments have also been performed which indicate that this approach is also suitable for the treatment or inhibition of experimental uveitis and autoimmune uveoretinitis These studies provide proof-of-concept for a novel low-cost oral ACE2 or Ang-(1-7) delivery system using transplastomic technology for pulmonary and ocular disease therapeutics. | ||||||
| 18 | MODIFIED ACE2 POLYPEPTIDES | EP14700370.1 | 2014-01-13 | EP2943216A1 | 2015-11-18 | LOIBNER, Hans; PEBALL, Bernhard; SCHUSTER, Manfred; STRANNER, Stefan |
| The present invention relates to modified angiotensin converting enzyme 2 (ACE2) polypeptides and pharmaceutical and analytical uses thereof. In particular, the present invention relates to Zn2+ depleted-, Zn2+ free-, mixed metal- and metal ion substituted-ACE2 as well as methods for the manufacture of these variants and uses thereof, such as therapeutic and analytic uses of these ACE2 variants. | ||||||
| 19 | 변형된 ＡＣＥ２ 폴리펩티드 | KR1020157021961 | 2014-01-13 | KR1020150110607A | 2015-10-02 | 로이프너,한스; 페발,베른하르트; 슈스터,만프레드; 슈트란너,슈테판 |
| 본발명은변형된앤지오텐신전환효소 2 (ACE2) 폴리펩티드및 이의약학적및 분석적용도에관한것이다. 특히, 본발명은 Zn고갈-, Zn비함유-, 혼합금속- 및금속이온치환-ACE2 뿐만아니라이러한변이체의제조방법및 이의용도, 예컨대이러한 ACE2 변이체의치료적및 분석적용도에관한것이다. | ||||||
| 20 | ORAL DELIVERY OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) OR ANGIOTENSIN-(1-7) BIOENCAPSULATED IN PLANT CELLS | PCT/US2014061428 | 2014-10-20 | WO2015058214A8 | 2016-06-09 | DANIELL HENRY; LI QIUHONG; RAIZADA MOHAN K |
| Low activity of angiotensin converting enzyme2 (ACE2) and its product, angiotensin-(1-7) [Ang-(1-7)] appear to contribute to pulmonary hypertension (PH). Long-term delivery of ACE2 or Ang-(1-7) require stability and ease of administration to increase patient compliance. Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect from acids and gastricenzymes and to facilitate absorption. Rats fed with bioencapsulated ACE2 or Ang-(1-7) exhibited improved heart function. A combination of ACE2 and Ang-(1-7) augmented the beneficial effects. Experiments indicate that this method is suitable for the treatmen or inhibition of experimental uveitis and autoimmune uveoretinitis These studies provide proof-of-concept for transplastomic technology as a novel low-cost oral ACE2 or Ang-(1-7) delivery system. | ||||||
QQ群二维码
意见反馈
意见反馈